Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.84
(
-1.80%
)
Bitcoin
74,397.09
(
0.61%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 151846

Wednesday, 01/27/2021 11:52:04 AM

Wednesday, January 27, 2021 11:52:04 AM

Post# of 257253
In blow to PFE, Xeljanz LT-safety_study_misses_non-inferiority_endpoints_compared_to_Humira/Enbrel:

https://finance.yahoo.com/news/pfizer-shares-co-primary-endpoint-114500861.html

The study in question was a post-marketing requirement from the FDA’s approval of Xeljanz in 2012. Whether Xeljanz’s label will be updated as a result of the study is unclear at this point.

Xeljanz has annualized worldwide sales of ~$2.5B.

p.s. “Shares” is evidently the new “updates” for biotech PRs bearing bad news.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now